Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses
- PMID: 38496296
- PMCID: PMC10940809
- DOI: 10.1016/j.isci.2024.109330
Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses
Abstract
Identifying immune modulators that impact neutralizing antibody responses against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is of great relevance. We postulated that high serum concentrations of soluble angiotensin-converting enzyme 2 (sACE2) might mask the spike and interfere with antibody maturation toward the SARS-CoV-2-receptor-binding motif (RBM). We tested 717 longitudinal samples from 295 COVID-19 patients and showed a 2- to 10-fold increase of enzymatically active sACE2 (a-sACE2), with up to 1 μg/mL total sACE2 in moderate and severe patients. Fifty percent of COVID-19 sera inhibited ACE2 activity, in contrast to 1.3% of healthy donors and 4% of non-COVID-19 pneumonia patients. A mild inverse correlation of a-sACE2 with RBM-directed serum antibodies was observed. In silico, we show that sACE2 concentrations measured in COVID-19 sera can disrupt germinal center formation and inhibit timely production of high-affinity antibodies. We suggest that sACE2 is a biomarker for COVID-19 and that soluble receptors may contribute to immune suppression informing vaccine design.
Keywords: Human specimen; Immune response; In silico biology; Properties of biomolecules.
© 2024 The Authors.
Conflict of interest statement
The Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité - Universitätsmedizin Berlin have filed three patent applications in connection with this work on which M.L., F.K., L.E.S., and K.D.L.R. (EP21155584.2); C.V.G. and K.D.L.R. (EP22164013.9); and M.L., C.R., C.V.G., and K.D.L.R. (EP21194414.5) are inventors.
Figures
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10940809/bin/fx1.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10940809/bin/gr1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10940809/bin/gr2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10940809/bin/gr3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10940809/bin/gr4.gif)
Similar articles
-
Concentrations of Soluble Angiotensin Converting Enzyme 2 (sACE2) in Children and Adults with and without COVID-19.J Clin Med. 2022 Nov 17;11(22):6799. doi: 10.3390/jcm11226799. J Clin Med. 2022. PMID: 36431276 Free PMC article.
-
Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.J Med Virol. 2021 Oct;93(10):5908-5916. doi: 10.1002/jmv.27144. Epub 2021 Jul 6. J Med Virol. 2021. PMID: 34138483 Free PMC article.
-
Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients.Rev Med Virol. 2021 Sep;31(5):1-12. doi: 10.1002/rmv.2213. Epub 2021 Jan 10. Rev Med Virol. 2021. PMID: 33426683 Free PMC article. Review.
-
Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls.Front Med (Lausanne). 2022 Dec 8;9:1058120. doi: 10.3389/fmed.2022.1058120. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36569121 Free PMC article.
-
Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection.Viruses. 2021 Nov 8;13(11):2243. doi: 10.3390/v13112243. Viruses. 2021. PMID: 34835049 Free PMC article. Review.
References
-
- Piccoli L., Park Y.-J., Tortorici M.A., Czudnochowski N., Walls A.C., Beltramello M., Silacci-Fregni C., Pinto D., Rosen L.E., Bowen J.E., et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183:1024–1042.e21. doi: 10.1016/j.cell.2020.09.037. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous